The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / July / Moving Beyond Document-Based Validation
Bioprocessing Interviews Regulation & Standards Standards & Regulation Quality & Compliance Technology & Manufacturing Sponsored

Moving Beyond Document-Based Validation

How UCB is improving traceability, audit readiness, and visibility.

07/02/2026 1 min read Video

Share

Slow workflows, fragmented tools, and repeated data entry can make global validation harder to manage and inspections more difficult to prepare for. How can companies create a faster, more traceable process without simply digitizing existing inefficiencies?

Nadia Williams, Head of IT Compliance Solutions at UCB, explains how the company is moving toward a centralized, record-based validation platform. She also discusses UCB’s pilot-led approach to change, ensuring standardization and audit readiness, and the future potential of automation and AI.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Michael May
Cell & Gene Development & Clinical Interviews
Musings from The Power List: Michael May

September 22, 2026

5 min read

CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy

The Barriers Limiting Radiopharmaceutical Access
Outsourcing Supply Chain Interviews
The Barriers Limiting Radiopharmaceutical Access

September 21, 2026

5 min read

From isotope supply to reimbursement, the practical challenges shaping real-world delivery in oncology

Musings from The Power List: Dajun Yang
Small Molecules Development & Clinical Interviews
Musings from The Power List: Dajun Yang

September 15, 2026

4 min read

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

Musings from The Power List: Ali Tavassoli
Small Molecules Drug Discovery Development & Clinical
Musings from The Power List: Ali Tavassoli

September 10, 2026

8 min read

Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: